InnoCan Pharma Corporation (CSE:INNO) ("Innocan Pharma" or the "Company"), a pharmaceutical technology company leveraging its novel cannabis-based therapeutics portfolio of targeted healing products, has announced the filing of its most recent patent application to the United States Patent and Trademark Office (USPTO). This move is in line with the Company's ongoing strategy to expand the breadth of its distinctive combined Cannabis and Magnesium topical pain-relief technology.

This latest continuation patent application encapsulates additional aspects of the Company's combined Magnesium and Cannabis-based solution, explicitly crafted for pain and itching alleviation. The patent application reflects the broad spectrum of Cannabinoids and variable dosage, underlining the promising potential of this novel technology.

InnoCan Pharma is committed to broadening its cannabis-based intellectual property portfolio further and intends to continue filing additional patent applications with the USPTO as well as other global patent offices. This innovative company continues to position itself at the forefront of novel cannabis-based therapeutic solutions.

"I am delighted to announce the submission of our latest patent application, further exemplifying our unwavering dedication to pushing the boundaries of pain relief technology", said CEO Iris Bincovich, "this patent represents the remarkable synergy between our combined Magnesium and Cannabis topical solution, showcasing a diverse range of cannabinoids and customizable dosages for optimal pain and itching alleviation. We persist in broadening our cannabis-based intellectual property portfolio and spearheading groundbreaking therapeutic solutions in the ever-evolving landscape of pharmaceutical technology."